Latest Headlines

Latest Headlines

FDA nixes melanoma use for PegIntron

Despite an advisory panel's recommendation, the FDA has declined to approve a new use for Schering-Plough's PegIntron, saying that it has "outstanding concerns" about a melanoma indication for the

FDA panel blesses new Pegintron use

Schering-Plough's liver drug Pegintron squeaked past an FDA advisory committee yesterday, narrowly winning a recommendation for a new indication for patients with advanced melanoma. The panel voted